Bristol-Myers Squibb Co
Biden administration's Medicare drug price negotiations will face major tests in 2024
Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna Moneymaker | Getty Images U.S. patients and drugmakers will get a first glimpse of how much Medicare can negotiate down drug prices in 2024, setting the […]
Read More
Karuna Therapeutics surges 47% following Bristol Myers Squibb announces $14 billion offer
Bristol Myers Squibb on Friday introduced it agreed to acquire biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 for every share. Karuna’s stock popped additional than 47% on the news Friday morning, hitting around $317 a share. Bristol Myers Squibb shares rose extra than 3%. The deal will assistance develop Bristol Myers’ […]
Read More
If you can't build the next Ozempic, buy it: Where M&A could be heading in the obesity drug space
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to themselves. But given the potential size of this opportunity, which some have put at more than $100 billion by 2030 , other pharmaceuticals companies — […]
Read More
Pfizer shares fall as 2024 revenue and profit forecast disappoints
Shares of Pfizer fell Wednesday after the drugmaker forecast 2024 revenue and profit below Wall Street’s expectations, as it sees weak demand for its once-blockbuster Covid products. Pfizer also raised the target of its sweeping cost-cutting plan by $500 million, bringing the anticipated total to $4 billion. The company expects 2024 revenue of $58.5 billion […]
Read More
Investing in Space: Why Amazon bought rocket launches from rival SpaceX
United Launch Alliance Atlas V rocket carrying the first two demonstration satellites for Amazon’s Project Kuiper broadband internet constellation stands ready for launch on pad 41 at Cape Canaveral Space Force Station on October 5, 2023 in Cape Canaveral, Florida, United States. Paul Hennessey | Anadolu Agency | Getty Images CNBC’s Investing in Space newsletter […]
Read More
Stocks making the most important moves midday: Microsoft, Chegg, Zoom Video clip, Paramount and extra
Check out out the firms building headlines in midday trading. Zoom Video clip Communications — The software stock included virtually 2% forward of its third-quarter earnings thanks right after industry shut. Analysts polled by FactSet expect $1.08 for every share in earnings and profits of $1.12 billion for the quarterly period, as opposed to the […]
Read More
Bristol Myers Squibb earnings top estimates even as top-selling drug fights generic competition
Bristol Myers Squibb on Thursday reported quarterly adjusted earnings that topped expectations and posted revenue in line with estimates, even as sales of the company’s popular blood cancer drug Revlimid plummeted due to generic competition. Bristol Myers, one of the world’s largest pharmaceutical companies, raked in $10.96 billion in revenue for the third quarter, down […]
Read More
These stocks are trying to solve a major shortcoming of weight loss drugs: Shrinking muscle mass
One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat. What this means for patients over the long term isn’t fully known, but there are several pharmaceutical companies studying the side effect and hoping to develop therapies that might regulate the condition. In […]
Read More
Evercore ISI says this biotech stock is a high risk, high reward play, with more than 200% upside
Evercore ISI initiated coverage of Aclaris Therapeutics , a clinical stage biotech working on immunology and inflammation drugs, at an outperform, saying the market is underpricing its odds for success heading into the release of clinical trial data. “We think the stock could trade up 300%+ on positive data (with more upside after the short-term […]
Read More
Drugmakers opt in to Medicare drug price negotiations – here’s what happens next
A pharmacist holds a bottle of the drug Eliquis, made by Pfizer Pharmaceuticals, at a pharmacy in Provo, Utah, January 9, 2020. George Frey | Reuters All drugmakers of the first 10 medicines selected for Medicare drug price negotiations have agreed to participate in the talks, even after many of them sued to halt the […]
Read More